Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Urol. Nov 24, 2014; 3(3): 249-257
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.249
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.249
Phosphodiesterase inhibitors for treatment of voiding dysfunction: An overview of experimental and clinical evidence
Ricardo Reges, Rommel Prata Regadas, João Batista Gadelha Cerqueira, Lúcio Flávio Gonzaga-Silva, Division of Urology, Universidade Federal of Ceara, Fortaleza, Ceara 60160-070, Brazil
Author contributions: Reges R and Regadas RP substantially contributed to conception and design, acquisition of data, analysis and interpretation of data; Reges R and Regadas RP drafted the article and revised it critically for important intellectual content; Reges R, Cerqueira JBG and Gonzaga-Silva LF approved the final version to be published.
Correspondence to: Ricardo Reges, MD, PhD, Division of Urology, Universidade Federal of Ceara, Antonele Bezerra st. Ap 1501. Meireles, Fortaleza, Ceara 60160-070, Brazil. consultoriodeurologia@gmail.com
Telephone: +55-85-32623730
Received: April 28, 2014
Revised: June 14, 2014
Accepted: July 17, 2014
Published online: November 24, 2014
Processing time: 204 Days and 19.3 Hours
Revised: June 14, 2014
Accepted: July 17, 2014
Published online: November 24, 2014
Processing time: 204 Days and 19.3 Hours
Core Tip
Core tip: In this study, an extensive review was performed on the use of phosphodiesterase inhibitors to treat lower urinary symptoms due to benign prostatic obstruction. This study explored experimental and recent clinical evidence in order to assist in the decision-making process in daily practice.